Copyright
©The Author(s) 2024.
世界华人消化杂志. 2024-08-28; 32(8): 608-615
在线出版 2024-08-28. doi: 10.11569/wcjd.v32.i8.608
在线出版 2024-08-28. doi: 10.11569/wcjd.v32.i8.608
临床参数 | n | |
年龄 | <60 | 17 |
≥60 | 18 | |
性别 | Male | 19 |
Female | 16 | |
临床分期 | Ⅰ-Ⅱ | 20 |
Ⅲ-Ⅳ | 15 | |
肿瘤大小 | <5 cm | 23 |
≥5 cm | 12 |
分组 | 抑制率/% | 克隆形成数/个 | 凋亡率/% | 迁移细胞数/个 | |
HGC-27 | si-NC | 0.00±0.00 | 112.52±6.25 | 8.07±0.47 | 169.89±10.80 |
si-circRASSF2 | 55.23±2.34a | 40.27±3.36a | 22.89±1.15a | 73.00±2.54a | |
miR-NC | 0.03±0.03 | 101.40±9.33 | 8.11±0.57 | 171.00±11.17 | |
miR-218-5p mimic | 44.19±2.70b | 42.26±4.11b | 19.78±1.13b | 85.78±3.91b | |
si-circRASSF2+anti-miR-NC | 55.01±2.75 | 37.21±3.38 | 23.06±1.36 | 69.56±3.47 | |
si-circRASSF2+miR-218-5p Inhibitor | 20.36±1.22c | 89.27±8.25c | 13.31±0.79c | 146.44±7.26c | |
AGS | si-NC | 0.00±0.00 | 55.26±6.42 | 5.64±0.67 | 116.51±12.14 |
si-circRASSF2 | 43.84±5.77a | 24.33±2.27a | 18.96±1.52a | 56.58±6.36a | |
miR-NC | 0.01±0.02 | 46.28±4.18 | 4.98±0.58 | 113.84±12.21 | |
miR-218-5p mimic | 45.26±5.10b | 18.22±2.14b | 19.27±2.21b | 52.27±5.95b | |
si-circRASSF2+anti-miR-NC | 44.1±4.5 | 19.33±1.74 | 19.04±2.02 | 57.43±6.27 | |
si-circRASSF2+miR-218-5p Inhibitor | 18.62±1.92c | 40.39±3.85c | 9.25±0.97c | 101.22±10.61c | |
F | 1569.442 | 375.574 | 429.625 | 379.610 | |
P | <0.05 | <0.05 | <0.05 | <0.05 |
引文著录: 骆超, 朱迪, 陈跃华. CircRASSF2靶向miR-218-5p调控胃癌细胞增殖、迁移和凋亡的研究. 世界华人消化杂志 2024; 32(8): 608-615